EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

Objective: To determine the effect of subcutaneous recombinant human erythropoietin on blood pressure in pre-dialysis chronic kidney disease (CKD) patients. Study Design: Case-series descriptive study. Place and Duration of Study: Combined Military Hospital Peshawar, from Mar 2016 to Sep 2016. Metho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Sajid Hussain, Qasim Raza, Muhammad Omer Aamir, Nadia Murtaza, Sadia Naureen, Mehwish Razzaq
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	anemia chronic kidney disease erythropoietin hypertension Medicine R Medicine (General) R5-920
Acceso en línea:	https://doi.org/10.51253/pafmj.v71i1.2489 https://doaj.org/article/200da42cfcd8473eb242201c91a2c6b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:200da42cfcd8473eb242201c91a2c6b5
record_format	dspace
spelling	oai:doaj.org-article:200da42cfcd8473eb242201c91a2c6b52021-12-02T15:08:46ZEFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTShttps://doi.org/10.51253/pafmj.v71i1.24890030-96482411-8842https://doaj.org/article/200da42cfcd8473eb242201c91a2c6b52021-02-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/2489https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the effect of subcutaneous recombinant human erythropoietin on blood pressure in pre-dialysis chronic kidney disease (CKD) patients. Study Design: Case-series descriptive study. Place and Duration of Study: Combined Military Hospital Peshawar, from Mar 2016 to Sep 2016. Methodology: A total of 100 cases were enrolled. Inclusion criteria was patients of 18 to 60 years of both gender & estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 having Hb <10g/dL and pre-dialysis while Exclusion Criteria was pregnancy or lactation, BP more than 140/90 mmHg, patients on Haemodialysis and worsening renal function. Baseline BP, body weight and eGFR of anaemic chronic kidney disease patients were recorded prior to EPO Alpha therapy. Erythropoiesis-stimulating agents (ESAs) i.e. EPO Alpha (50-100 Units/kg thrice or once weekly) was administered subcutaneously. Subsequent blood pressure, body weight and eGFR monitoring was done after 2 and 4 weeks post EPO Alpha injection. Results: Mean age range was 46.71 years with range of 20-60 years, 73 (73%) were male while 27 (27%) were females. Mean ± SD for other quantitative variables like eGFR was 23.12 ± 5.28, Hb levels (g/dL) was 8.62 ± 0.85, Weight (kg) was 56.66 ± 6.62 and duration of CKD was 9.87 ± 4.02. Frequency of Hypertension (post EPO) was 2 (2%) and p-value was 0.453. Conclusion: We concluded that the frequency of hypertension in pre-dialysis patients with chronic kidney disease (CKD) receiving recombinant human erythropoietin (rhEPo) subcutaneously (SC) in low doses, is very low, so rhEPo can be used subcutaneously for treatment of anemia in pre-dialysis CKD patientsMuhammad Sajid HussainQasim RazaMuhammad Omer AamirNadia MurtazaSadia NaureenMehwish RazzaqArmy Medical College Rawalpindiarticleanemiachronic kidney diseaseerythropoietinhypertensionMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 2, Pp 261-265 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anemia chronic kidney disease erythropoietin hypertension Medicine R Medicine (General) R5-920
spellingShingle	anemia chronic kidney disease erythropoietin hypertension Medicine R Medicine (General) R5-920 Muhammad Sajid Hussain Qasim Raza Muhammad Omer Aamir Nadia Murtaza Sadia Naureen Mehwish Razzaq EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
description	Objective: To determine the effect of subcutaneous recombinant human erythropoietin on blood pressure in pre-dialysis chronic kidney disease (CKD) patients. Study Design: Case-series descriptive study. Place and Duration of Study: Combined Military Hospital Peshawar, from Mar 2016 to Sep 2016. Methodology: A total of 100 cases were enrolled. Inclusion criteria was patients of 18 to 60 years of both gender & estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 having Hb <10g/dL and pre-dialysis while Exclusion Criteria was pregnancy or lactation, BP more than 140/90 mmHg, patients on Haemodialysis and worsening renal function. Baseline BP, body weight and eGFR of anaemic chronic kidney disease patients were recorded prior to EPO Alpha therapy. Erythropoiesis-stimulating agents (ESAs) i.e. EPO Alpha (50-100 Units/kg thrice or once weekly) was administered subcutaneously. Subsequent blood pressure, body weight and eGFR monitoring was done after 2 and 4 weeks post EPO Alpha injection. Results: Mean age range was 46.71 years with range of 20-60 years, 73 (73%) were male while 27 (27%) were females. Mean ± SD for other quantitative variables like eGFR was 23.12 ± 5.28, Hb levels (g/dL) was 8.62 ± 0.85, Weight (kg) was 56.66 ± 6.62 and duration of CKD was 9.87 ± 4.02. Frequency of Hypertension (post EPO) was 2 (2%) and p-value was 0.453. Conclusion: We concluded that the frequency of hypertension in pre-dialysis patients with chronic kidney disease (CKD) receiving recombinant human erythropoietin (rhEPo) subcutaneously (SC) in low doses, is very low, so rhEPo can be used subcutaneously for treatment of anemia in pre-dialysis CKD patients
format	article
author	Muhammad Sajid Hussain Qasim Raza Muhammad Omer Aamir Nadia Murtaza Sadia Naureen Mehwish Razzaq
author_facet	Muhammad Sajid Hussain Qasim Raza Muhammad Omer Aamir Nadia Murtaza Sadia Naureen Mehwish Razzaq
author_sort	Muhammad Sajid Hussain
title	EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
title_short	EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
title_full	EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
title_fullStr	EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
title_full_unstemmed	EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
title_sort	effect of subcutaneous recombinant human erythropoietin on blood pressure in pre-dialysis chronic kidney disease (ckd) patients
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doi.org/10.51253/pafmj.v71i1.2489 https://doaj.org/article/200da42cfcd8473eb242201c91a2c6b5
work_keys_str_mv	AT muhammadsajidhussain effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients AT qasimraza effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients AT muhammadomeraamir effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients AT nadiamurtaza effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients AT sadianaureen effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients AT mehwishrazzaq effectofsubcutaneousrecombinanthumanerythropoietinonbloodpressureinpredialysischronickidneydiseaseckdpatients
_version_	1718387987508625408

EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

Ejemplares similares